There is one clinical trial.
Noninvasive ventilation(NIV) is an important treatment to the respiratory failure patients.The severe Corona Virus Disease-19(COVID-19) patients are incline to respiratory failure.The NIV may reduce the intubtion rate.This research was taken to investigate the factor to the success of the noninvasive ventilation to the COVID-19 patients with respiratory failure.
Description: the sucess rate of the noninvasive ventilationMeasure: success rate Time: 4 month
Description: the intubtion rate of the COVID-19 patientsMeasure: the intubtion rate Time: 4 month
Description: blood lymphocyte of the COVID-19 patientsMeasure: blood lymphocyte Time: 4month
Description: blood B-type natriuretic peptide of the COVID-19 patientsMeasure: B-type natriuretic peptide Time: 4 month
Description: blood procalcitonin of the COVID-19 patientsMeasure: Procalcitonin Time: 4 month
Description: Oxygen Saturation of the COVID-19 patientsMeasure: Oxygen Saturation Time: 4 month
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports